Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04713982
PHASE2/PHASE3

Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

Sponsor: Vanderbilt University Medical Center

View on ClinicalTrials.gov

Summary

Examine the effects of deutetrabenazine on functional speech and gait impairment

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2021-11-19

Completion Date

2026-10-01

Last Updated

2026-01-21

Healthy Volunteers

No

Interventions

DRUG

Deutetrabenazine

Maximum dose of 48mg/day or up to 36 mg/d if receiving a strong CYP2D6 inhibitor

Locations (1)

Vanderbilt University Medical Center

Nashville, Tennessee, United States